Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
| Previous Close | 4.0500 |
| Open | 2.9000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's Range | 2.7000 - 3.2800 |
| 52 Week Range | 0.8100 - 10.0100 |
| Volume | 14,454,691 |
| Avg. Volume | 5,177,580 |
| Market Cap | 1.804B |
| Beta (5Y Monthly) | -0.50 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
View moreRelated Research
- GuruFocus.com
10 Best and Worst Performing Biotechs Amid Covid-19
Here we take a look at the top ten best and worst performing biotech stocks this year Continue reading...
- GlobeNewswire
Update on HIV-BLA-PDUFA: FDA requested more information to complete a substantive review. No additional trials required. CytoDyn plans to submit the requested information and will ask for a Type A meeting with the FDA per the agency’s suggestion
Update on COVID-19: CytoDyn is planning to lock and unblind the Phase 2 COVID-19 trial data later this week. Periodic safety review by Data Safety Monitoring Committee (DSMC).
- GuruFocus.com
Biggest Year-to-Date CEO Sells
2 CEOs see price change losses since their sales Continue reading...
© 2021 Verizon Media. All rights reserved.
